Evidence map›Paper›PMID 35796863›Full record

SynthesisCancer immunology, immunotherapy : CII2023

Efficacy and safety of chimeric antigen receptor T-cells treatment in central nervous system lymphoma: a PRISMA-compliant single-arm meta-analysis.

Liwei Lv, Yuchen Wu, Han Shi, Xuefei Sun, Zixin Deng, Hongjia Huo, Ruonan Li, Yuanbo Liu

Abstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Cancer immunology, immunotherapy : CII, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Novel Therapies for Primary Central Nervous System Lymphomas.Current neurology and neuroscience reports · 2024
    Review
  6. Article
  7. Updates of primary central nervous system lymphoma.Therapeutic advances in hematology · 2024
    Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Liwei LvDepartment of Hematology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Yuchen WuDepartment of Hematology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Han ShiDepartment of Hematology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Xuefei SunDepartment of Hematology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Zixin DengDepartment of Hematology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Hongjia HuoDepartment of Hematology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Ruonan LiDepartment of Hematology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Yuanbo LiuDepartment of Hematology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. yuanbol@ccmu.edu.cn.

Funding

Capital's Funds for Health Improvement and Research NO.2020-2-2049
6 · The paper itself

Abstract

backgroundChimeric antigen receptor (CAR) T cells are used to treat refractory and recurrent B-cell lymphoma. When administered intravenously, CAR T cells can be detected in cerebrospinal fluid, and thus represent a promising method for the treatment of central nervous system lymphoma (CNSL). This meta-analysis aimed to clarify the effectiveness and safety of CAR T-cell therapy in the treatment of CNSL.

methodsStudies involving patients with CNSL who received CAR T-cell therapy that reported overall response (OR), complete response (CR), and partial response (PR) were included. A random-effects or fixed-effects model with double arcsine transformation was used for the pooled analysis and 95% confidence intervals (CI) were determined for all outcomes.

resultsEight studies, comprising 63 patients, were identified and were included in the meta-analysis. The pooled OR and CR rates after treatment with CAR T cells were 69% (95% CI, 56-81%) and 51% (95% CI, 37-64%), respectively. The pooled rate of progressive disease after remission was 38% (95% CI, 21-55%). The pooled rate for neurotoxicity grade 3 or above was 12% (95% CI, 3-24%, I

conclusionsCAR T-cell therapy is a promising option for the treatment of CNSL owing to a high short-term remission rate and controllable side effects. However, the high recurrence rate after remission must be addressed. Long-term follow-up data with large sample sizes are also needed to better assess the effectiveness and safety of CAR T-cell therapy. REGISTRATION: This meta-analysis was registered in the international prospective register of systematic reviews (PROSPERO) (CRD42022301332).

Indexed as

Lymphoma, B-CellReceptors, Chimeric AntigenAntigens, CD19Central Nervous SystemHumansImmunotherapy, AdoptiveNeoplasm Recurrence, LocalT-LymphocytesAntigens, CD19Receptors, Chimeric AntigenCAR T cellsCentral nervous system lymphomaMeta-analysisSingle-arm

Identifiers

PMID35796863
PMCPMC10991213

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.